ALK and neoplasm: Forthcoming studies should take up the challenge of confirming if clinically relevant formulations of silibinin (e.g., silibinin complexed with the amino-sugar meglumine; silibinin-phosphatidylcholine, the phytolipid delivery system Siliphos; and Eurosil85/Euromed, a milk thistle extract that is the active component of the nutraceutical Legasil with enhanced bioavailability [102]) could similarly abrogate the ALK–TKIs-refractory tumor growth in vivo.